AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34775413 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 475
Study 33991802 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii
Number of subjects: 20
Study 33991802 — intervention group
Group type: COMPARATOR
Intervention: C (Cycloergometer)
Number of subjects: 20
Study 33991802 — intervention group
Group type: COMPARATOR
Intervention: T (Treadmill)
Number of subjects: 20
Study 32629007 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (COMPASS trial)
Number of subjects: 9126
Study 32629007 — intervention group
Group type: COMPARATOR
Intervention: Low-dose aspirin (IMRD-UK cohort)
Number of subjects: 9126
Study 35020938 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Women over 50 Online program
Number of subjects: 62
Study 35020938 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 62
Study 33059915 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Number of subjects: 179
Study 33059915 — intervention group
Group type: EXPERIMENTAL
Intervention: High-grade tumors
Number of subjects: 179
Study 33059915 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 179
Study 33059915 — intervention group
Group type: EXPERIMENTAL
Intervention: Median follow-up
Number of subjects: 179
Study 36384218 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-intensity telecare collaborative pain management (TCM)
Number of subjects: 820
Study 36384218 — intervention group
Group type: COMPARATOR
Intervention: Higher-intensity integrated pain team management (IPT)
Number of subjects: 820
Study 36384218 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to buprenorphine
Number of subjects: 820
Study 36384218 — intervention group
Group type: COMPARATOR
Intervention: No option to switch to buprenorphine
Number of subjects: 820
Study 33810904 — intervention group
Group type: EXPERIMENTAL
Intervention: Salk-Sabin-Sabin group
Number of subjects: 360
Study 33810904 — intervention group
Group type: COMPARATOR
Intervention: Salk-Salk-Salk group
Number of subjects: 360
Study 35652929 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippotherapy combined with Schroth exercises
Number of subjects: 45
Study 35652929 — intervention group
Group type: COMPARATOR
Intervention: Schroth exercises alone
Number of subjects: 45
Study 32152202 — intervention group
Group type: EXPERIMENTAL
Intervention: hu14.18‐IL2 immunotherapy (Group A)
Number of subjects: 23
Study 32152202 — intervention group
Group type: COMPARATOR
Intervention: hu14.18‐IL2 immunotherapy (Group B)
Number of subjects: 23
Study 34845502 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg abiraterone with a low-fat meal (LOW)
Number of subjects: 72
Study 34845502 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg abiraterone fasting (STD)
Number of subjects: 72
Study 32105198 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Microscopy (VM)
Number of subjects: 71
Study 32105198 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional Microscopy (CM)
Number of subjects: 71
Study 32105198 — intervention group
Group type: COMPARATOR
Intervention: Control group (no workshop)
Number of subjects: 71
Study 35212104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin
Number of subjects: 68
Study 35212104 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 68
Study 35507948 — intervention group
Group type: EXPERIMENTAL
Intervention: Chandelier-Assisted Scleral Buckling (CSB)
Number of subjects: 49
Study 35507948 — intervention group
Group type: COMPARATOR
Intervention: Standard Scleral Buckling (SSB)
Number of subjects: 49
Study 34714505 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal prevention program
Number of subjects: 678
Study 34895218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fevipiprant 150 mg
Number of subjects: 2538
Study 34895218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fevipiprant 450 mg
Number of subjects: 2538
Study 34895218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2538
Study 32706124 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavior therapy (CBT) for anxiety related to asthma, 10-week protocol
Number of subjects: 6
Study 32706124 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavior therapy (CBT) for anxiety related to asthma
Number of subjects: 6
Study 34488318 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone + VR
Number of subjects: 43
Study 34488318 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 43
Study 34488318 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study 32448894 — intervention group
Group type: EXPERIMENTAL
Intervention: Stopping prophylaxis when CD4 count was above 200 cells/µL for more than 3 months
Number of subjects: 4813
Study 32448894 — intervention group
Group type: COMPARATOR
Intervention: Stopping prophylaxis when the patient was virologically suppressed (two consecutive HIV RNA ≤ 400c/mL)
Number of subjects: 4813
Study 35361632 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g of methylprednisolone intravenously for 3 consecutive days
Number of subjects: 304
Study 34065751 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-life parent-child activities
Number of subjects: 323
Study 34065751 — intervention group
Group type: EXPERIMENTAL
Intervention: Child-alone screen use duration
Number of subjects: 323
Study 34065751 — intervention group
Group type: EXPERIMENTAL
Intervention: Video game exposure
Number of subjects: 323
Study 34065751 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-screen recreational parent-child activities
Number of subjects: 323
Study 33001206 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibody titers in sequential samples from serum donors recovering from COVID-19
Number of subjects: 0
Study 35588357 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus breathing exercises (UC 1 BrEX)
Number of subjects: 193
Study 33068350 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection of houttuynia cordata (3 mL each time, once a day for 3 injections, then once every two days for 3 times)
Number of subjects: 60
Study 33068350 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears and anti-inflammatory drugs
Number of subjects: 60
Study 35779545 — intervention group
Group type: EXPERIMENTAL
Intervention: If I Were Jack (gender-transformative relationships and sexuality education)
Number of subjects: 8216
Study 35779545 — intervention group
Group type: COMPARATOR
Intervention: Standard RSE (control)
Number of subjects: 8216
Study 33530252 — intervention group
Group type: EXPERIMENTAL
Intervention: Baduanjin exercise training
Number of subjects: 90
Study 33530252 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving any special exercise training)
Number of subjects: 90
Study 34118745 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 34
Study 34118745 — intervention group
Group type: COMPARATOR
Intervention: Young adults
Number of subjects: 34
Study 32446263 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (lower dosage) in cesarean-born neonates (CDL)
Number of subjects: 26
Study 32446263 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (higher dosage) in cesarean-born neonates (CDH)
Number of subjects: 26
Study 32446263 — intervention group
Group type: COMPARATOR
Intervention: Cesarean delivery neonates (CD)
Number of subjects: 26
Study 32446263 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (both dosages)
Number of subjects: 26
Study 32446263 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 26
Study 32352828 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared book reading at 6 months
Number of subjects: 293
Study 32352828 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 293
Study 35217772 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 2.0 mg once weekly plus dapagliflozin 10 mg once daily
Number of subjects: 56
Study 35217772 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 56
Study 35217772 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide plus dapagliflozin
Number of subjects: 56
Study 32091358 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated vaccine schedule (0 and 21 days)
Number of subjects: 0
Study 32091358 — intervention group
Group type: COMPARATOR
Intervention: Longer interval vaccine schedule (0 and 60 days)
Number of subjects: 0
Study 35869375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine vaping products (NVPs) for 12 weeks
Number of subjects: 29
Study 34847965 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ketamine
Number of subjects: 0
Study 34847965 — intervention group
Group type: COMPARATOR
Intervention: Intravenous magnesium sulfate
Number of subjects: 0
Study 33122529 — intervention group
Group type: EXPERIMENTAL
Intervention: LMWH combined with insulin
Number of subjects: 476
Study 33122529 — intervention group
Group type: COMPARATOR
Intervention: Insulin alone
Number of subjects: 476
Study 36039334 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting radiation-associated aspiration pneumonia (RAP)
Number of subjects: 453
Study 35854638 — intervention group
Group type: EXPERIMENTAL
Intervention: Palovarotene 10/5 mg
Number of subjects: 40
Study 35854638 — intervention group
Group type: EXPERIMENTAL
Intervention: Palovarotene 5/2.5 mg
Number of subjects: 40
Study 35854638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33320369 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane extract
Number of subjects: 2
Study 33320369 — intervention group
Group type: COMPARATOR
Intervention: Control (amniotic membrane extract vehicle)
Number of subjects: 2
Study 33663274 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual flow speed at 7.5 km.h-1
Number of subjects: 18
Study 33663274 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual flow speed at 15 km.h-1
Number of subjects: 18
Study 33663274 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual flow speed at 22.5 km.h-1
Number of subjects: 18
Study 32675583 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 150
Study 32675583 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 150
Study 32675583 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment group
Number of subjects: 150
Study 34475143 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepectoral implant-based breast reconstruction (IBBR)
Number of subjects: 372
Study 34475143 — intervention group
Group type: COMPARATOR
Intervention: Subpectoral implant-based breast reconstruction (IBBR)
Number of subjects: 372
Study 33045009 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement of stakeholders in the design, evaluation, and dissemination of learning resources.
Number of subjects: 0
Study 33045009 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of stakeholder engagement effectiveness.
Number of subjects: 0
Study 35603694 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented reality coupled pamphlet
Number of subjects: 60
Study 35603694 — intervention group
Group type: COMPARATOR
Intervention: Simple pamphlet
Number of subjects: 60
Study 33392650 — intervention group
Group type: EXPERIMENTAL
Intervention: Tethered cord syndrome (TCS) group
Number of subjects: 151
Study 33392650 — intervention group
Group type: COMPARATOR
Intervention: Control group (300 randomly selected examinees)
Number of subjects: 151
Study 33392650 — intervention group
Group type: EXPERIMENTAL
Intervention: TCS group
Number of subjects: 151
Study 33415556 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and surgery
Number of subjects: 0
Study 33415556 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Number of subjects: 0
Study 33415556 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 33415556 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation
Number of subjects: 0
Study 33589674 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocoa flavanols (260, 510, and 770 mg/day) for 12 weeks
Number of subjects: 211
Study 33589674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 33589674 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI substudy
Number of subjects: 211
Study 32868525 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 991
Study 32868525 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (Control)
Number of subjects: 991
Study 32868525 — intervention group
Group type: EXPERIMENTAL
Intervention: G3 tumors in the microsatellite stable/microsatellite instability-low subset
Number of subjects: 991
Study 36069785 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral therapy (ICBT) course (5-week duration)
Number of subjects: 308
Study 36069785 — intervention group
Group type: COMPARATOR
Intervention: Motivational interviewing (MI) before treatment
Number of subjects: 308
Study 36069785 — intervention group
Group type: COMPARATOR
Intervention: Self-guided booster lesson (1 month after treatment)
Number of subjects: 308
Study 33140132 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Care Model (TCM) components
Number of subjects: 39
Study 32092190 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise rehabilitation (supervised 3 times a week for 16 weeks)
Number of subjects: 55
Study 32092190 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise rehabilitation
Number of subjects: 55
Study 32092190 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic exercise
Number of subjects: 55
Study 32092190 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 55
Study 32092190 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene control (in-person discussion and monthly phone calls)
Number of subjects: 55
Study 34719577 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol gel 1%
Number of subjects: 11
Study 34719577 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol gel 5%
Number of subjects: 11
Study 34719577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 32761810 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation
Number of subjects: 24
Study 32761810 — intervention group
Group type: COMPARATOR
Intervention: Open flap mechanical debridement, supracrestal implantoplasty, bone grafting, and acellular dermal matrix membrane (Control group)
Number of subjects: 24
Study 32761810 — intervention group
Group type: EXPERIMENTAL
Intervention: No/minor membrane exposure
Number of subjects: 24
Study 36451472 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery according to the ECASES system
Number of subjects: 202
Study 36451472 — intervention group
Group type: COMPARATOR
Intervention: Surgery according to the operator's experience
Number of subjects: 202
Study 34292643 — intervention group
Group type: EXPERIMENTAL
Intervention: ozanimod 0.46 mg or 0.92 mg daily
Number of subjects: 1346
Study 34292643 — intervention group
Group type: COMPARATOR
Intervention: interferon β‐1a 30 µg weekly
Number of subjects: 1346
Study 34292643 — intervention group
Group type: EXPERIMENTAL
Intervention: ozanimod
Number of subjects: 1346
Study 33105368 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic (Bacillus subtilis) supplementation (DE111; 5 billion CFU/day)
Number of subjects: 23
Study 33105368 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 23
Study 33849654 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheport
Number of subjects: 164
Study 33849654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ada
Number of subjects: 164
Study 36326860 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current stimulation (IF), applied 3 days a week for 8 weeks
Number of subjects: 25
Study 36326860 — intervention group
Group type: COMPARATOR
Intervention: Sham IF, applied 3 days a week for 8 weeks
Number of subjects: 25
Study 34360284 — intervention group
Group type: EXPERIMENTAL
Intervention: High-traffic (HT) area exposure to traffic-related air pollution (TRAP)
Number of subjects: 0
Study 34360284 — intervention group
Group type: COMPARATOR
Intervention: Low-traffic (LT) area exposure to traffic-related air pollution (TRAP)
Number of subjects: 0
Study 32800307 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-Rated TranS-C Checklist
Number of subjects: 101
Study 32800307 — intervention group
Group type: COMPARATOR
Intervention: Independent-Rater TranS-C Checklist
Number of subjects: 101
Study 36064434 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 0
Study 36064434 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 36064434 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol
Number of subjects: 0
Study 36064434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32530041 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-Based Financing (PBF) intervention
Number of subjects: 0
Study 32530041 — intervention group
Group type: COMPARATOR
Intervention: Decentralized Facility Financing (DFF)
Number of subjects: 0
Study 32890302 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Chair Stand test
Number of subjects: 248
Study 32890302 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance tests and PROMs
Number of subjects: 248
Study 32890302 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical performance tests
Number of subjects: 248
Study 33834318 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART initiation (EAAA)
Number of subjects: 2261
Study 33834318 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (ART eligibility below a CD4 count threshold)
Number of subjects: 2261
Study 35026498 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF mouthwash
Number of subjects: 91
Study 35026498 — intervention group
Group type: COMPARATOR
Intervention: Salt and Soda mouthwash
Number of subjects: 91
Study 35026498 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt and Soda during prevention followed by GM‐CSF at onset of OM
Number of subjects: 91
Study 34050843 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term residential exposure to air pollution (PM2.5, O3, SO2, NO2, and PM2.5 constituents OC, NH4, NO3, SO4)
Number of subjects: 2681
Study 34050843 — intervention group
Group type: COMPARATOR
Intervention: Control group (age- and sex-matched individuals without Hodgkin lymphoma)
Number of subjects: 2681
Study 32880842 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC + GTO
Number of subjects: 32
Study 32880842 — intervention group
Group type: COMPARATOR
Intervention: MPC
Number of subjects: 32
Study 34427177 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory kinesiotaping (KT)
Number of subjects: 30
Study 34427177 — intervention group
Group type: COMPARATOR
Intervention: Control (no taping)
Number of subjects: 30
Study 32826634 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance (RES) training
Number of subjects: 84
Study 32826634 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance (END) training
Number of subjects: 84
Study 32826183 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin MELT
Number of subjects: 130
Study 32826183 — intervention group
Group type: COMPARATOR
Intervention: Enuresis alarm
Number of subjects: 130
Study 36429671 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-weekly resilience-enhancement program (four 2-h sessions)
Number of subjects: 123
Study 33964898 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram including T stage, N stage, grade, radiotherapy, and chemotherapy
Number of subjects: 6419
Study 33964898 — intervention group
Group type: COMPARATOR
Intervention: AJCC 8th staging system
Number of subjects: 6419
Study 35167386 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip bandage reducing flexion, adduction, and internal rotation of the hip
Number of subjects: 99
Study 35167386 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 99
Study 33270193 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized DNA sequences
Number of subjects: 0
Study 32017599 — intervention group
Group type: EXPERIMENTAL
Intervention: SIT (sprint interval training)
Number of subjects: 40
Study 32017599 — intervention group
Group type: EXPERIMENTAL
Intervention: Need-support condition
Number of subjects: 40
Study 32017599 — intervention group
Group type: COMPARATOR
Intervention: MICT (moderate-intensity continuous training)
Number of subjects: 40
Study 36008173 — intervention group
Group type: EXPERIMENTAL
Intervention: Ring External Fixator (Group I)
Number of subjects: 32
Study 36008173 — intervention group
Group type: COMPARATOR
Intervention: OssiproÒ gentamicin intramedullary interlocking tibial nail (Group II)
Number of subjects: 32
Study 34037459 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle education (LS)
Number of subjects: 232
Study 34037459 — intervention group
Group type: COMPARATOR
Intervention: Stress reduction guided imagery (SRGI)
Number of subjects: 232
Study 34037459 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle behavior guided imagery (LBGI)
Number of subjects: 232
Study 34037459 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 232
Study 35238796 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure blood flow restriction
Number of subjects: 89
Study 35238796 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate pressure blood flow restriction
Number of subjects: 89
Study 35238796 — intervention group
Group type: COMPARATOR
Intervention: Sham pressure
Number of subjects: 89
Study 35143902 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokine adsorption
Number of subjects: 41
Study 35143902 — intervention group
Group type: COMPARATOR
Intervention: Control (no cytokine adsorption)
Number of subjects: 41
Study 33426576 — intervention group
Group type: EXPERIMENTAL
Intervention: Living high-training low (LHTL) group (n=9)
Number of subjects: 18
Study 33426576 — intervention group
Group type: COMPARATOR
Intervention: Living low-training low (LLTL) group (n=9)
Number of subjects: 18
Study 33426576 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18